Daiichi Sankyo Company, Limited (DSNKY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Tokyo, Japan. El CEO actual es Hiroyuki Okuzawa.
DSNKY tiene fecha de IPO 2008-12-12, 18,726 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $34.34B.
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, engaged in the research, development, manufacturing, and marketing of a diverse portfolio of prescription and over-the-counter medicines. The company's key therapeutic areas include oncology, cardiology, diabetes, neurology, and infectious diseases, with notable products such as trastuzumab deruxtecan for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo also operates in vaccines, animal health, cosmetics, medical devices, and active pharmaceutical ingredients. Founded in 1899, the company leverages strategic collaborations, including partnerships with diagnostic companies, to expand its competitive position in precision medicine and advanced therapies across major global markets.
